Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer patients want financial screening early in care, study finds

2.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

3.

No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances

4.

A new blood test greatly increases the ability to detect cancer.

5.

Is Chemotherapy via Peripheral IV Access More Effective Than Central Lines for Testicular Cancer?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot